- Home
- AZ vs RNA Comparison
AZ vs RNA Comparison
Compare AZ & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AZ | RNA |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.6M | 222.5M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | AZ | RNA |
|---|---|---|
| Price | $5.55 | $10.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 20 |
| Target Price | $15.00 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 493.8K | 269.6K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $532.60 | $88.12 |
| Revenue Next Year | $178.94 | $18.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.97 | $10.00 |
| 52 Week High | $9.10 | $73.06 |
Technical Indicators
Market Signals| Indicator | AZ | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 40.36 | 29.99 |
| Support Level | $5.14 | N/A |
| Resistance Level | $6.67 | $14.39 |
| Average True Range (ATR) | 0.36 | 0.74 |
| MACD | -0.11 | -0.47 |
| Stochastic Oscillator | 13.55 | 4.43 |
Price Performance
Historical ComparisonAbout AZ A2Z Smart Technologies Corp.
A2Z Cust2Mate Solutions Corp is engaged in creating shopping carts. With the help of a user-friendly smart algorithm, touch screen, and other technologies, the company streamlines the retail shopping experience by scanning purchased products and enabling in-cart payment so that customers can simply pick & go, and bypass long cashier checkout lines.
About RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.